A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Inclusion Criteria:

• Have a diagnosis of chronic plaque psoriasis for at least 6 months before the firstadministration of study drug. Duration since diagnosis may be reported by theparticipant

• Participant has stable moderate to severe plaque psoriasis (body surface area [BSA] >10, Psoriasis Area and Severity Index [PASI] >10, and Dermatology Quality of LifeIndex [DLQI] >10) with or without psoriatic arthritis at Baseline

• Must be naïve to and candidate for systemic therapy, as assessed by the investigator

• Participant has an inadequate response, intolerance or contraindication to topicalpsoriasis treatment

Exclusion Criteria:

• Participants with non-plaque forms of psoriasis

• Participant has previously received systemic therapy for psoriasis, whether biologicor non-biologic or photochemotherapy

• Active systemic infection during the last 2 weeks (exception: common cold) prior toscreening.

• Any documented active or suspected malignancy or history of malignancy within 5 yearsprior to screening, except appropriately treated basal or squamous cell carcinoma ofthe skin or in situ carcinoma of uterine cervix

• Participant has any condition or contraindication to Fumaderm that would preclude thepatient's participation in the present study